UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924

Journal of clinical oncology, 2001-05, Vol.19 (10), p.2638-2646

2001

Volltextzugriff (PDF)

Disease-Free Survival of Patients with Muscle Invasive Bladder Cancer Treated by Radical Cystectomy vs. Bladder-Sparing Therapy at a Nationwide Level

International journal of radiation oncology, biology, physics, 2022-11, Vol.114 (3), p.e204

2022

Volltextzugriff (PDF)

989TiP - KEYNOTE-905: A phase III study of cystectomy plus perioperative pembrolizumab versus cystectomy alone in cisplatin (cis)-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC)

Annals of oncology, 2019-10, Vol.30, p.v401-v401

2019

Volltextzugriff (PDF)

KEYNOTE-905: A phase III study of cystectomy plus perioperative pembrolizumab versus cystectomy alone in cisplatin (cis)-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC)

Annals of oncology, 2019-10, Vol.30, p.v401

2019

Volltextzugriff (PDF)

Improved Detection of Urothelial Carcinoma In Situ With Hexaminolevulinate Fluorescence Cystoscopy

The Journal of urology, 2004, Vol.171 (1), p.135-138

2004

Volltextzugriff (PDF)

A0854 - Consistencies in follow-up after radical cystectomy for bladder cancer: A practice-based framework by collaborative EAU bladder cancer guideline panels

European urology, 2024-03, Vol.85, p.S1887-S1888

2024

Volltextzugriff (PDF)

Consistencies in follow-up after radical cystectomy for bladder cancer: A practice-based framework by collaborative EAU bladder cancer guideline panels

European urology, 2024-03, Vol.85, p.S1887-S1888

2024

Volltextzugriff (PDF)

IMPROVED DETECTION AND TREATMENT OF BLADDER CANCER USING HEXAMINOLEVULINATE IMAGING: A PROSPECTIVE, PHASE III MULTICENTER STUDY

The Journal of urology, 2005-09, Vol.174 (3), p.862-866

2005

Volltextzugriff (PDF)

989TiPKEYNOTE-905: A phase III study of cystectomy plus perioperative pembrolizumab versus cystectomy alone in cisplatin (cis)-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

A Phase III, randomized, double-blind, multicenter study of adjuvant nivolumab vs placebo in patients (pts) with high-risk invasive urothelial carcinoma (UC; CheckMate 274)

Annals of oncology, 2017-09, Vol.28, p.v327-v327

2017

Volltextzugriff (PDF)

CMR 2005: 2.06: Ferumoxtran-10 enhanced MR imaging in detection of metastases outside the normal surgical area in prostate cancer

Contrast media and molecular imaging, 2006-03, Vol.1 (2), p.57-57

2006

Volltextzugriff (PDF)

949 Radiofrequence induced hyperthermia chemotherapy (RIHTC) in high-risk non-muscle invasive bladder cancer (NMIBC): Multiinstitutional, international outcome analysis of 271 treated patients with a follow-up time of more than 2 years

European urology supplements : official journal of the European Association of Urology, 2015-04, Vol.14 (2), p.e949-e949a

2015

Volltextzugriff (PDF)

830 Clinical validation of a gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter study

European urology supplements : official journal of the European Association of Urology, 2015-04, Vol.14 (2), p.e830-e830

2015

Volltextzugriff (PDF)

Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.5148-5148

2009

Volltextzugriff (PDF)

Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.5019-5019

2007

Volltextzugriff (PDF)

No Large-Scale Germline Genomic Aberrations in Hereditary Bladder Cancer Patients with High Resolution Array-Based CGH

American journal of epidemiology, 2006-06, Vol.163 (suppl_11), p.S110-S110

2006

Volltextzugriff (PDF)

Satraplatin: A new treatment option for patients with hormone refractory prostate cancer

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.4802-4802

2005

Volltextzugriff (PDF)

Active surveillance: Off-protocol selection increases the risk of unfavorable outcomes

European urology supplements : official journal of the European Association of Urology, 2018-03, Vol.17 (2), p.e775

2018

Volltextzugriff (PDF)

536 - Active surveillance: Off-protocol selection increases the risk of unfavorable outcomes

European urology supplements : official journal of the European Association of Urology, 2018-03, Vol.17 (2), p.e775-e775

2018

Volltextzugriff (PDF)

P042 - Dutch practice patterns of active surveillance for prostate cancer: Is there a relationship between protocol adherence and oncological outcomes?

European urology supplements : official journal of the European Association of Urology, 2017-11, Vol.16 (10), p.e2680-e2680

2017

Volltextzugriff (PDF)

Dutch practice patterns of active surveillance for prostate cancer: Is there a relationship between protocol adherence and oncological outcomes?

European urology supplements : official journal of the European Association of Urology, 2017-11, Vol.16 (10), p.e2680

2017

Volltextzugriff (PDF)

Seven year update of an EORTC phase III trial of high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.4528-4528

2005

Volltextzugriff (PDF)

SATRAPLATIN (S) INCREASES PROGRESSION-FREE SURVIVAL (PFS) AND DELAYS PAIN PROGRESSION IN PATIENTS (PTS) WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC) THAT HAVE PROGRESSED AFTER PRIOR DOCETAXEL

European urology supplements : official journal of the European Association of Urology, 2008, Vol.7 (3), p.230-230

2008

Volltextzugriff (PDF)

Evaluation of the clinical value of Urinary NMP22 as a marker in the screening and surveillance of transitional cell carcinoma of the Urinary Bladder. Commentary

European urology, 2001, Vol.40 (4), p.415-421

2001

Volltextzugriff (PDF)

Ketoconazole high dose in management of hormonally pretreated patients with progressive metastatic prostate cancer

Urology (Ridgewood, N.J.), 1989-05, Vol.33 (5), p.411-415

1989

Volltextzugriff (PDF)

1 – 25 von 485

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(436)
Mit Volltextzugriff
(373)

Publikationsform

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Disease-Free Survival of Patients with Muscle Invasive Bladder Cancer Treated by Radical Cystectomy vs. Bladder-Sparing Therapy at a Nationwide Level

989TiP - KEYNOTE-905: A phase III study of cystectomy plus perioperative pembrolizumab versus cystectomy alone in cisplatin (cis)-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC)

KEYNOTE-905: A phase III study of cystectomy plus perioperative pembrolizumab versus cystectomy alone in cisplatin (cis)-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC)

Improved Detection of Urothelial Carcinoma In Situ With Hexaminolevulinate Fluorescence Cystoscopy

A0854 - Consistencies in follow-up after radical cystectomy for bladder cancer: A practice-based framework by collaborative EAU bladder cancer guideline panels

Consistencies in follow-up after radical cystectomy for bladder cancer: A practice-based framework by collaborative EAU bladder cancer guideline panels

IMPROVED DETECTION AND TREATMENT OF BLADDER CANCER USING HEXAMINOLEVULINATE IMAGING: A PROSPECTIVE, PHASE III MULTICENTER STUDY

989TiPKEYNOTE-905: A phase III study of cystectomy plus perioperative pembrolizumab versus cystectomy alone in cisplatin (cis)-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC)

A Phase III, randomized, double-blind, multicenter study of adjuvant nivolumab vs placebo in patients (pts) with high-risk invasive urothelial carcinoma (UC; CheckMate 274)

CMR 2005: 2.06: Ferumoxtran-10 enhanced MR imaging in detection of metastases outside the normal surgical area in prostate cancer

949 Radiofrequence induced hyperthermia chemotherapy (RIHTC) in high-risk non-muscle invasive bladder cancer (NMIBC): Multiinstitutional, international outcome analysis of 271 treated patients with a follow-up time of more than 2 years

830 Clinical validation of a gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter study

Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial

Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial

No Large-Scale Germline Genomic Aberrations in Hereditary Bladder Cancer Patients with High Resolution Array-Based CGH

Satraplatin: A new treatment option for patients with hormone refractory prostate cancer

Active surveillance: Off-protocol selection increases the risk of unfavorable outcomes

536 - Active surveillance: Off-protocol selection increases the risk of unfavorable outcomes

P042 - Dutch practice patterns of active surveillance for prostate cancer: Is there a relationship between protocol adherence and oncological outcomes?

Dutch practice patterns of active surveillance for prostate cancer: Is there a relationship between protocol adherence and oncological outcomes?

Seven year update of an EORTC phase III trial of high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors

SATRAPLATIN (S) INCREASES PROGRESSION-FREE SURVIVAL (PFS) AND DELAYS PAIN PROGRESSION IN PATIENTS (PTS) WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC) THAT HAVE PROGRESSED AFTER PRIOR DOCETAXEL

Evaluation of the clinical value of Urinary NMP22 as a marker in the screening and surveillance of transitional cell carcinoma of the Urinary Bladder. Commentary

Ketoconazole high dose in management of hormonally pretreated patients with progressive metastatic prostate cancer

Suchergebnisse filtern